1. Anti-infection
    Cell Cycle/DNA Damage
  2. HCV
    DNA/RNA Synthesis
  3. Filibuvir

Filibuvir 

Cat. No.: HY-10118 Purity: ≥99.0%
Handling Instructions

Filibuvir is an orally active, selective non-nucleoside inhibitor of the HCV nonstructural 5B protein (NS5B) RNA-dependent RNA polymerase (RdRp). Filibuvir binds noncovalently in the thumb II allosteric pocket of NS5B. Filibuvir inhibits genotype 1a and 1b replicons with EC50s of 59 nM for both isoforms, respectively. Filibuvir preferentially inhibits elongative RNA synthesis and potently decreases viral RNA accumulation.

For research use only. We do not sell to patients.

Filibuvir Chemical Structure

Filibuvir Chemical Structure

CAS No. : 877130-28-4

Size Price Stock Quantity
1 mg USD 80 In-stock
Estimated Time of Arrival: December 31
5 mg USD 240 In-stock
Estimated Time of Arrival: December 31
10 mg   Get quote  
50 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Based on 1 publication(s) in Google Scholar

Top Publications Citing Use of Products

Publications Citing Use of MCE Filibuvir

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Filibuvir is an orally active, selective non-nucleoside inhibitor of the HCV nonstructural 5B protein (NS5B) RNA-dependent RNA polymerase (RdRp). Filibuvir binds noncovalently in the thumb II allosteric pocket of NS5B. Filibuvir inhibits genotype 1a and 1b replicons with EC50s of 59 nM for both isoforms, respectively[1]. Filibuvir preferentially inhibits elongative RNA synthesis and potently decreases viral RNA accumulation[2].

In Vitro

Filibuvir (0.01-10000 nM; 48 h) inhibits the WT 1b replicon in a dose-dependent manner, with an EC50 of ∼70 nM in Huh7.5 cells harboring the HCV replicon. Filibuvir binds to the HCV polymerase with a dissociation constant of 29 nM[2].
Filibuvir preferentially inhibits elongative RNA synthesis rather than de novo-initiated RNA synthesis. Filibuvir has no obvious effect on de novo-initiated RNA synthesis (IC50=∼5 μM) but decreases primer extension from PE46, with an IC50 of 73 nM[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial
Molecular Weight

503.64

Formula

C₂₉H₃₇N₅O₃

CAS No.
SMILES

O=C(O1)C(CC2=NN(C(C)=C3)C(N=C3C)=N2)=C(O)C[[email protected]@]1(C4CCCC4)CCC5=CC(CC)=NC(CC)=C5

Shipping

Room temperature in continental US; may vary elsewhere.

Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
References

Purity: ≥99.0%

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Keywords:

FilibuvirHCVDNA/RNA SynthesisHepatitis C virusOrallyNS5BRdRpRNAthumb IIrepliconInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email address *

Phone number *

 

Organization name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Filibuvir
Cat. No.:
HY-10118
Quantity:
MCE Japan Authorized Agent: